Skip to main content

Machatha Stephen's Form 4/A amendment

Amended

Aldeyra Therapeutics, Inc.ALDX · filed Apr 17, 2024

Accession no.
0000950170-24-045113
Filed
Apr 17, 2024
Trade date
Mar 12, 2024
Filing delay
36 days
Rule 10b5-1 plan
Not checked
Original filed
Mar 12, 2024

This filing lists 1 non-derivative transaction. It carries over 2 transactions from the original filing that it did not restate. Open-market sales total $98.6K. It was filed 36 days after the trade.

This amendment restates part of 0000950170-24-030311 (filed Mar 12, 2024). The transactions it did not restate still count and are listed below.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Machatha StephenCIK 0001836354Officer (Chief Development Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 12, 2024Common StockSSaleDisposed−11,537$3.16F2−$36,456.92252,812Direct

Carried over from the original filing

This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.

From 0000950170-24-030311 (filed Mar 12, 2024).

Non-derivative securities (Table I)

Non-derivative transactions carried over from 0000950170-24-030311
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 11, 2024Common StockSSaleDisposed−18,231$3.41F2−$62,167.71255,032Direct

Derivative securities (Table II)

Derivative transactions carried over from 0000950170-24-030311
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 9, 2024Common StockAGrant or awardAcquired+405,450$0.00$0405,450Direct

Footnotes on the original

The footnotes that the prices of these transactions refer to on the original filing.

F2

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards. This sale was previously reported in the Reporting Person's Form 4 filed on March 12, 2024 (the "Original Form 4").

F2

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.11 to $3.31. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Referenced by the price of 1 transaction in Table I.

F3

Adjusted to reflect 9,317 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan, which were inadvertently omitted in the Original Form 4. The amount in Column 5 of this Form 4 reflects the number of shares beneficially owned by the Reporting Person as of the date of this report after giving effect to the adjustment.

Read the full filing on SEC EDGAR (opens in a new tab)